CONTRIBUTORS - Home - Springer978-1-4899-1813...A.B. Hancock, Jr. Memorial Laboratory for Cancer Research Department of Biochemistry Center in Molecular Toxicology Vanderbilt Univ

CONTRIBUTORS

Farhat Abbas Postgraduate School of Pharmacology University of Bradford Bradford, West Yorkshire, BD7 lDP United Kingdom

Eva Ahlbom Department of Cell Biology Pharmacia AB Biopharmaceuticals S-I12 87 Stockholm, Sweden

Makoto Aihara Department of Biochemistry The University of Tokyo Bunkyo-ku, Tokyo 113, Japan

Keiichi Akatsuka Department of Neurosurgery Tottri University 86 Nishi-Machi Yonago, 683 Japan

Kunihiro Akimaru Department of Experimental Pediatrics The University of Texas M.D. Anderson Cancer Center 1515 Holcombe Blvd. Houston, TX 77030

Petra Ambs Biochemisches Institut c/o Klinik fUr Tumorbiologie Universitat Freiburg Breisacherstr. 117 D-79106 Freiburg, Germany

Zayheda Amin Postgraduate School of Pharmacology University of Bradford Bradford, West Yorkshire, BD7 IDP United Kingdom

Y.Aoki Life Science Research Laboratory Japan Tobacco Inc. 6-2 Umegaoka, Aoba-ku Yokohama, Kanagawa 227, Japan

Toshiya Arakawa Department of Biochemistry School of Medicine University of Tokushima Kuramoto-Cho, Tokushima 770, Japan

Seiji Arase Tokushima University Department of Dermatology Kuramoto-cho, Tokushima, 770 Japan

M. Baccarini Biochemisches Institut c/o Klinik fUr Tumorbiologie Universit1it Freiburg Breisacherstr. 117 D-79106 Freiburg, Germany

Jesus Balsinde Depts. of Chemistry and Biochemistry Revelle College and School of Medicine University of California at San Diego La Jolla, CA 92029-0601

567

568

Johannes Barsig Faculty of Biology University of Konstanz 78343 Konstanz, Germany

Jutta Belkner Institute of Biochemistry University Clinics (Charite) Humboldt Universitiit Hessische Str. 3-4 10115 Berlin, Germany

Robert M. Bell Glaxo Wellcome Inc. Research Triangle Park Alexander, NC 27709

M. Belley Merck Frosst Centre for Therapeutic

Research P.O. Box 1005, Pointe Claire-Dorval Quebec, H9R 4P8 Canada

M. Beltramo The Neurosciences Institute 10640 John J. Hopkins Drive San Diego, CA 92121

T. Bisogno Istituto di Cibemetica Biologico & Istituto di Cibemetica, C.N.R. Viale Toiano 6, 80072 Arco Felice Naples, Italy

w.e. Black Merck Frosst Centre for Therapeutic


M. Blomster Departments of Medical Biochemistry and

Biophysics Karolinska Institutet S-171 77 Stockholm, Sweden

Larisa B. Bondarenko Institute of Biochemistry University Clinics (Charite) Humboldt Universitat Hessische Str. 3-4 10 115 Berlin, Germany

Suzanne Borgers

Contributors

Division of Tumor Biochemistry Deutsches Krebsforschungszentrum D-69120 Heidelberg, Germany

Suzanne Borgers Division of Tumor Biochemistry Deutsches Krebsforschungszentrum D-69120 Heidelberg, Germany

Jean Pierre Bourreau Department of Physiology Hong Kong University Hong Kong

Roland Brinckmann Institute of Biochemistry Univ. Clinics (Charite) Humboldt University 10098 Berlin, Germany

Deborah M. Brown Immunology and Thoracic Oncology

Programs of the Cancer Center Departments of Microbiology and

Immunology University of Rochester School of Medicine and Dentistry Rochester, New York, USA 14642

Hal E. Broxmeyer Walther Oncology Center Indiana University School of Medicine Indianapolis, IN

Heinz Burgmann Department of Infectious Diseases University of Vienna Waehringer Guertel 18-20 A-1090 Vienna, Austria

Contributors

Robert M. Burk Depts. of Bioiological Sciences and

Medicinal Chemistry Allergan Inc. Irvine CA 92713

Igor Butovich Institute of Biochemistry University Clinics (Charite) Humboldt Universitat Hessische Str. 3-4 10115 Berlin, Germany

H. Cadas The Neurosciences Institute 10640 John J. Hopkins Drive San Diego, CA 92121

Denis M. Callewaert Oxford Biomedical Research Avon Industrial Drive Rochester Hills, MI 48309

Mairead A. Carroll Department of Pharmacology New York Medical Co liege Valhalla, NY 10595

Rabindranath Chakrabarti Department of Cell Biology School of Medicine University of California Davis, CA 95616-8643

Alvin C. Chan Department of Biochemistry University of Ottawa Ottawa, KIH 8M5, Canada

Chi-Chung Chan Merck Frosst Centre for Therapeutic


Kam-ming Chan Department of Pharmacology The Chinese University of Hong Kong Shatin, Hong Kong

Chi-Chung Chan Department of Pharmacology Merck Frosst Centre for Therapeutic

Research Kirkland, Quebec, H9H 3L Canada

569

and P.O. Box 1005, Pointe Claire-Dorval Quebec, H9R 4P8

Julia W. Chang Dept. of Neurobiology & Anatomy University of Rochester School of Medicine and Dentistry Rochester, NY 14642

Wen-Chang Chang Department of Pharmacology College of Medicine National Cheng Kung University Tainan, Taiwan 70101

s. Charleson Merck Frosst Centre for Therapeutic


Ben-Kuen Chen Department of Pharmacology College of Medicine National Cheng Kung University Tainan, Taiwan 70101

Ching-Jiunn Chen Department of Pharmacology College of Medicine National Cheng Kung University Tainan, Taiwan 70101

Nan Chiang Division of Medicinal Chemistry and

Pharmaceutics College of Pharmacy University of Kentucky Lexington, KY 40536-0082

570

Q. Choudhury Department of Biochemical Pharmacology Medical School of St. Bartholomew's

Hospital Charterhouse Square, London EC1M 6BQ United Kingdom

Patrick C. Choy Faculty of Medicine University of Manitoba 770 Bannatyne Ave. Winnipeg, Manitoba, R3E OW3, Canada

Patricia C. Chulada Nat'l. Inst. of Environmental Health

Sciences Research Triangle Park, NC 27709

Kristi S. Clark Oxford Biomedical Research Avon Industrial Drive Rochester Hills, MI 48309

RalfClaus Pharmazeutisch-Chemisches Institut Universitat Heidelberg 69120 Heidelberg, Germany

Paul D. Coleman Dept. of Neurobiology and Anatomy University of Rochester School of Medicine and Dentistry Rochester, NY 14642

Brenda C. Crews A.B. Hancock, Jr. Memorial Laboratory for

Cancer Research Department of Biochemistry Center in Molecular Toxicology Vanderbilt Univ. School of Medicine Nashville, TN 37232-0146

J. D. Crostall Department of Biochemical Pharmacology Medical School of St. Bartholomew's

Hospital Charterhouse Square, London EC1M 6BQ United Kingdom

Eva Danielsson Department of Cell Biology Pharmacia AB Biopharmaceuticals S-112 87; Stockholm, Sweden

Barbara J. Davis

Contributors

Nat'l. Inst. of Environmental Health Sciences

Research Triangle Park, NC 27709

Hans P. Deigner Pharmazeutisch-Chemisches Institut Universitat Heidelberg 69120 Heidelberg, Germany

D. Denis Merck Frosst Centre for Therapeutic


Edward A. Dennis Department of Chemistry and

Biochemistry Revelle College and School of Medicine University of California at San Diego La Jolla, CA 92029-0601

L. DeProcellis Istituto di Cibernetica Biologico & Istituto di Cibernetica,

C.N.R. Viale Toiano 6, 80072, Arco Felice Naples, Italy

F. Desarnaud The Neurosciences Institute 10640 John 1. Hopkins Drive San Diego, CA 92121

David DeWitt Department of Biochemistry Michigan State University East Lansing, MI48824-1224

Contributors

Peter Dieter Biochemisches Institut c/o Klinik fUr Tumorbiologie Universitat Freiburg Breisacherstr. 117 D-79106 Freiburg, Germany

V. DiMarzo Istituto per la Chimica di Molecole di

Interesse Biologico Viale Toiano 6, 80072, Arco Felice Naples, Italy

Teresa Duda The Unit of Regulatory & Molecular

Biology University of Medicine & Dentistry ofNJ School of Osteopathic Medicine 2 Medical Center Drive Stratford, NJ 08084

Gareth Edwards Department of Plastic and Reconstructive

Surgery Faculty of Medicine University of Medicine University of the Orange Free State Bloemfontein, South Africa 9300

Kent L. Erickson Department of Cell Biology School of Medicine University of California Davis, CA 95616-8643

Angela L. Everhart Laboratory of Molecular Biophysics National Institute of Environmental Health

ScienceslNIH Research Triangle Park Alexander, NC 27709

Eric R. Fedyk Immunology and Thoracic Oncology


Immunology University of Rochester School of Medicine and Dentistry Rochester, New York, USA 14642

Lili Feng Department of Immunology The Scripps Research Institute Baton Rouge, LA 70808

William R. Ferrell Institute of Biomedical & Life Sciences University of Glasgow Scotland, G 12 8QQ United Kingdom

Susan M. Fischer Department of Carcinogenesis University of Texas M.D. Anderson Cancer Center Science Park-Research Division Smithville, TX 78957

Edith Fitzke Biochemisches Institut c/o Klinik fUr Tumorbiologie Universitat Freiburg Breisacherstr. 117 D-79106 Freiburg, Germany

R. J. Flower Department of Biochemical

Pharmacology Medical School of St. Bartholomew's

Hospital

571

Charterhouse Square, London EC 1 M 6BQ United Kingdom

Gerhard Fiirstenberger Depts. of Membrane Research and

Biophysics The Weizmann Institute of Science Rehovot, Israel FSP II Tumor Regulation DKFZ, Heidelberg D6900, Germany

572

Kyoji Furuta Department of Chemistry Nagoya University Nagoya 464-01, Japan

Beatrix Fyrnys Pharmazeutisch-Chemisches Institut Universitat Heidelberg 69120 Heidelberg, Germany

S. Gaillet The Neurosciences Institute 10640 John J. Hopkins Drive San Diego, CA 92121

J. Y. Gauthier Merck Frosst Centre for Therapeutic

Research P.O. Box 1005 Pointe Claire-Dorval Quebec, H9R 4P8 Canada

GerhardKolde Institute of Biochemistry Univ. Clinics (Charite) Universitat Humboldt 10098 Berlin, Germany

Xiang Gao Depts. Of Radiation Oncology & Pathology Wayne State University School of Medicine 431 Chemistry Building Detroit, MI 48202

W. Gerwick Oregon State University Corvallis, OR 97331

Burhan I. Ghanayem N afl. Inst. of Environmental Health


Sujoy Ghosh Glaxo Wellcome Inc. Research Triangle Park Alexander, NC 27709

Contributors

A.H. Gilani The Aga Khan University Depts. of Pharmacology and Physiology Stadium Road Karachi-74800, Pakistan 3500

Wayne C. Glasgow Laboratory of Molecular Biophysics National Institute of Environmental

Health ScienceslNIH Research Triangle Park Alexander, RTP, NC 27709

R. Goldman Depts. of Membrane Research and

Biophysics The Weizmann Institute of Science Rehovot, Israel

F. Gonzalez-Crussi Department of Pathology Children's Memorial Hospital Northwestern University Medical School Chicago, IL 60614

R. Gordon Merck Frosst Centre for Therapeutic


Wolfgang Graninger Department of Infectious Diseases University of Vienna Waehringer Guertel 18-20 A-I090 Vienna, Austria

Patrick W. Gray ICOS Corporation 22021 20th Avenue S.E. Bothell, WA 98021

D. Guay Merck Frosst Centre for Therapeutic


Contributors

G.H. Gurtner Department of Physiology and Medicine New York Medical College Valhalla, NY 10595

J. Z. Haeggstrem Department of Medical Biochemistry and


Wolfgang Hagmann Division of Tumor Biochemistry Deutsches Krebsforschungszentrum D-69120 Heidelberg, Germany

P. Hamel Merck Frosst Centre for Therapeutic


Yusuf A. Hannun Departments of Medicine and Cell Biology Duke University Medical Center Durham, NC 27710

Noriko Hara School of Pharmaceutical Sciences Showa University, 1-5-8 Hatanodai Shin~gawa-ku, Tokyo 142, Japan

Yoko Hayashi Department of Biochemistry School of Medicine The University ofTokushima Kuramoto-Cho, Tokushima 770, Japan

Harvey R. Herschman University of California at Los Angeles Los Angeles, CA 90095

Dagmar Heydeck Institute of Biochemistry Univ. Clinics (Charite) Universitiit Humboldt 10098 Berlin, Germany

573

Aizan Hirai The 2nd Department of Internal Medicine Chiba University School of Medicine Chiba, Japan

Manfred Hlousek Department of Infectious Diseases University of Vienna Waehringer Guertel 18-20 A-I090 Vienna, Austria

Jonathan K. S. Ho Department of Surgery The Chinese University of Hong Kong Shatin New Territories Shatin, Hong Kong

Jan Holmberg Department of Cell Biology Pharmacia AB Biopharmaceuticals S-112 87, Stockholm, Sweden

Kenneth V. Honn Department of Pathology 431 Chemistry Building Wayne State University Detroit, MI 48202

Tomokatsu Hori Department of Neurosurgery Touri University 86 Nishi-Machi Yonago, 683 Japan

Angela D. Howard Department of Cell Biology School of Medicine University of California Davis, CA95616-8643

Wei Hsueh Department of Pathology Children's Memorial Hospital Northwestern University Medical School Chicago, IL 60614

574

Chifu Huang Division of Medicinal Chemistry and


Neil E. Hubbard Department of Cell Biology School of Medicine University of California Davis, CA 95616-8643

Millie Hughes-Fulford Department of Medicine Univ. of California-San Francisco and Laboratory of Cell Growth (151F) Veterans Affairs Medical Center San Francisco, CA

Daniel Hwang Pennington Biomedical Research Center Baton Rouge, LA 70808

Hiroyasu Inoue Department of Pharmacology National Cardiovascular Center Research Institute Fujishiro-dai, Suita, Osaka 565, Japan

Keizo Inoue School of Pharmaceutical Sciences Showa University, 1-5-8 Hatanodai Shinagawa-ku, Tokyo 142, Japan

Satoshi Ishii Department of Biochemistry Faculty of Medicine The University of Tokyo Hong'n 7-3-1, Bunkyo-ku, Tokyo 113, Japan

Toshihisa Ishikawa Department of Experimental Pediatrics The University of Texas M.D. Anderson Cancer Center 1515 Holcombe Blvd Houston, TX 77030

Kazunori Ishimura Department of Anatomy Tokushima University 3-18-15 Karamoto-cho Tokushima, 770 Japan

Masato Iwatsuki Department of Neurosurgery Tottri University 86 Nishi-Machi Yonago, 683 Japan

Takashi Izumi Department of Biochemistry Faculty of Medicine The University of Tokyo Hongo 7-3-1, Bunkyo-ku Tokyo 113, Japan

Takashi Izumi Department of Biochemistry Faculty of Medicine The University of Tokyo Tokyo 113, Japan

Byeong C. Jang

Contributors

Pennington Biomedical Research Center Baton Rouge, LA 70808

Francis T. Jay Faculty of Medicine University of Manitoba 770 Bannatyne Ave. Winnipeg, Manitoba R3E OW3, Canada

Xiao-Qing Jia Xing-Ya Pharmaceutical Co., Ltd Guangdong, China

John M. Johnston Univ. of Texas Southwestern Med. Ctr. Biochemistry Department 5323 Harry Hines Blvd. Dallas, TX 75235-9051

Contributors

Robert L. Jones Department of Pharmacology The Chinese University of Hong Kong Shatin, Hong Kong

David Kagawa Depts. of Radiation Oncology, Pathology

and Chemistry Wayne State University Detroit, MI 48202

Hans E. Kaiser Department of Pathology School of Medicine University of Maryland at Baltimore Baltimore, MD

Gabor Kaley Department of Physiology and Medicine New York Medical College Valhalla, NY 10595

Amit S. Kalgutkar A.B. Hancock, Jr. Memorial Laboratory for

Cancer Research Department of Biochemistry Center in Molecular Toxicology Vanderbilt Univ. School of Medicine Nashville, TN 37232-0146

W.Kan Department of Phamacology College of Medicine National Cheng Kung University Tainan City, Tainan Taiwan 70101, R.O.C.

S. Kargman Merck Frosst Centre for Therapeutic


Koji Kishimoto Department of Biochemistry School of Medicine University of Tokushima Kuramoto-Cho Tokushima 770, Japan

Thomas Klein Department of Pediatrics Universitat Hospital Deutschlausstr. 12 35037 Marburg, Germany

H. Kodama Life Science Research Laboratory Japan Tobacco Inc. 6-2 Umegaoka, Aoba-ku Yokohama Kanagawa 227, Japan

Gerhard Kolde Department of Dermatology Virchow Clinics Humboldt University 13344 Berlin, Germany

Achim H-P Krauss Depts. of Biological Sciences and


Ichiro Kudo School of Pharmaceutical Sciences Showa University, 1-5-8 Hatanodai Shinagawa-ku Tokyo 142, Japan

Hartmut Kiihn Institute of Biochemistry University Clinics (Charite) Humboldt Universitat 10098 Berlin, Germany

575

576

Kazuhiko Kume Department of Biochemistry Faculty of Medicine The University of Tokyo Hongo 7-3-1, Bunkyo-ku, Tokyo 113, Japan

Masayoshi Kumegawa Department of Oral Anatomy Meikai University School of Dentistry Sakado, Saitama 350-02, Japan

Yuko Kurahashi Department of Biochemistry Tokushima University School of Medicine Tokushima 770, Japan

Martine Lafrance Department of Obstetrics & Gynaecology

and Physiology University of Ottawa Loeb Medical Research Institute Ottawa Civic Hospital Ottawa, Ontario, Canada Kl Y 4E9

Staffan Lake Department of Molecular Biology Pharmacia AB Biopharmaceuticals S-112 87, Stockholm, Sweden

Robert Langenbach Laboratory of Experimental Carcinogenesis

& Mutagenesis Research Triangle Park, 101 Alexander, RTP, NC 27709

H.Y.A.Lau Department of Pharmacology Faculty of Medicine Chinese University of Hong Kong Shatin, New Territories, Hong Kong

C.K.Lau Merck Frosst Centre for Therapeutic


Contributors

Y. Leblanc Merck Frossst Centre for Therapeutic


Christopher A. Lee Nat'\. Inst. of Environmental Health


Edmund Lee Faculty of Medicine University of Manitoba 770 Bannatyne Ave. Winnipeg, Manitoba R3E OW3, Canada

Hsheng-Kai Lee Department of Pharmacology Nat'\. Def. Medical Center Taipei, Taiwan, R.O.C.

YuLi Union Hospital Tongji Medical University Whan, 430030, P.R.C.

Ming Li Department of Obstetrics & Gynaecology

and Physiology University of Ottawa Loeb Medical Research Institute Ottawa Civic Hospital Ottawa, Ontario Canada KIY 4E9

Julang Li Department of Obstetrics & Gynaecology


Contributors

Bangyan Li-Stiles Department of Carcinogenesis University of Texas M.D. Anderson Cancer Center Science Park-Research Division Smithville, TX 78957

King-Teh Lin Department of Cell Biology University of Medicine & Dentistry ofNJ School of Osteopathic Medicine 2 Medical Center Drive Stratford, NJ 08084

Vi-Wen Liu Department of Pharmacology College of Medicine National Cheng Kung University Tainan, Taiwan 70101

Herng-Hsiang Lo Department of Carcinogenesis University of Texas M.D. Anderson Cancer Center Science Park-Research Division Smithville, TX 78957

Charles D. Loftin Nat'l. lnst. of Environmental Health


Louise Louw Department of Anatomy and Cell

Morphology Faculty of Medicine University of Medicine Univrsity of the Orange Free State Bloemfontein, South Africa 9300

Li Lu Dept. of Radiation Oncology Walther Oncology Center 975 W. Walnut St., Rm. 501 Indianapolis, IN 46202

LiLu Departments of Medicine School of Medicine University of Maryland at Baltimore Baltimore, MD

Joel Mahler Nat'l. Inst. of Environmental Health

Sciences Laboratory of Experimental

Carcinogenesis and Mutagenesis Research Triangle Park, NC 27709

Ricky Y.K. Man Faculty of Medicine University of Manitoba

577

770 Bannatyne Ave., Winnipeg, Manitoba R3E OW3, Canada

J. Mancini Merck Frosst Centre for Therapeutic


Lawrence J. Marnett A.B. Hancock, Jr. Memorial Laboratory

for Cancer Research Department of Biochemistry Center in Molecular Toxicology Vanderbilt Univ. School of Medicine Nashville, TN 37232-0146

Kay Marshall Postgraduate School of Pharmacology University of Bradford Bradford, West Yorkshire, BD7 IDP United Kingdom

S. Maurelli Istituto per la Chimica di Molecole di

Interesse Biologico Viale Toiano 6, 80072 Arco Felice, Naples, Italy

John C. McGiff Department of Pharmacology New York Medical College Valhalla, NY 10595

578

C. L. Meng Department of Dentistry Tri-Serv. General Hospital Taipei, Taiwan, R.O.C.

Scott G. Morham Department of Pathology University of N.C. at Chapel Hill Chapel Hill, NC 27599-7525

Mikiro Mori Department of Biochemistry The University of Tokyo Bunkyo-ku Tokyo 113, Japan

Ikuo Morita Department of Physiological Chemistry Graduate School Tokyo Medical and Dental University Yushima l-chome Bunkyo-ku Tokyo 113, Japan

S.Moshonov Depts. of Membrane Research and


R. Moshonov FSP II Tumor Regulation DKFZ Heidelberg D6900, Germany

M.J. Mueller Departments of Medical Biochemistry and


Kouei Muguruma Univ. of Texas Southwestern Med. Ctr. Biochemistry Department 5323 Harry Hines Blvd. Dallas, TX 75235-9051

Contributors

Makoto Murakami School of Pharmaceutical Sciences Showa University, 1-5-8 Hatanodai Shinagawa-ku Tokyo 142, Japan

Seiitsu Murato Department of Physiological Chemistry Graduate School Tokyo Medical And Dental Univ. Yushima, Bunkyo-ku Tokyo 113, Japan

Sei-itsu Murota Department of Physiological Chemistry Graduate School Tokyo Medical and Dental University Yushima l-chome Bunkyo-ku Tokyo 113, Japan

T.F. Murray Oregon State University Corvallis, OR 97331

Hiroyuki Mutoh Department of Biochemistry University of Tokyo Tokyo 113" Japan

Hamid Najafipour Department of Physiology Kerman University of Medical Sciences Kerman, Iran

Eiichi Nakajima Analytical and Metabolic Research Laboratories Sankyo Corporation Limited Japan

Michihiro Nakamura Department of Biochemistry University of Tokoshima School of Medicine Kuramoto-Cho Tokushima 770, Japan

Contributors

Montonao Nakamura Department of Biochemistry Faculty of Medicine The University of Tokyo Hongo 7-3-1 Bunkyo-ku Tokyo 113, Japan

Makoto Nakanishi Department of Bichemistry Jichi Medical School Tochigi 329-04, Japan

Yoshihito Nakatani School of Pharmaceutical Sciences Showa University, 1-5-8 Hatanodai Shinagawa-ku Tokyo 142, Japan

S. P. Newman Gene Transcription Lab. ICRF Molecular Oncology Unit Hammersmith Hospital Duccane Road, London W12 ONN United Kingdom

Makoto Nishiyama Department of Neurosurgery Tottri University 86 Nishi-Machi Yonago, 683 Japan

Raymond F. Novak The Institute of Chemical Toxicology 2727 Second Avenue Detroit, MI 48201

Ryoji Noyori Department of Chemistry Nagoya University Nagoya 464-01, Japan

Rolf M. Niising Department of Pediatrics University Hospital 35037 Marburg, Germany

Rolf M. Niising Department of Pediatrics University Hospital Deutsch1ausstr. 12 35037 Marburg, Germany

Lina M. Obeid Departments of Medicine and Cell

Biology Duke University Medical Center Durham, NC 27710

Anett Ocklind Pharmacia Pharmaceuticals S-75182 Uppsala, Sweden

Yoko Ogawa Department of Biochemistry Faculty of Medicine The University of Tokyo Tokyo 113, Japan

Sergey A. Oghiy Institute of Biochemistry University Clinics (Charite) Humboldt Universitat Hessische Str. 3-4 10115 Berlin, Germany

Hisayo Okamoto Department of Neurosurgery Tottri University 86 Nishi-Machi Yonago, 683 Japan

M. Kerry O'Banion Depts. of Neurology and Neurobiology

and Anatomy University of Rochester School of Medicine and Dentistry Rochester, NY 14642

M. Ouellet Merck Frosst Centre for Therapeutic


579

580

D. Percival Merck Frosst Centre for Therapeutic


Richard P. Phipps Immunology and Thoracic Oncology


Immunology Environmental Medicine and Pediatrics

University of Rochester School of Medicine and Dentistry Rochester, New York 14642

D. Piomelli The Neurosciences Institute 10640 John J. Hopkins Drive San Diego, CA 92121

Arthur T. Porter Department of Radiation Oncology Wayne State University 431 Chemistry Building Detroit, MI 48202 P. Prasit Merck Frosst Centre for Therapeutic


Elisabeth Presterl Department of Infectious Diseases University of Vienna Waehringer Guertel 18-20 A-1090 Vienna, Austria

Yue-ming Qian Department of Pharmacology The Chinese University of Hong Kong Shatin, Hong Kong

Contributors

Xiao-wu Qu Department of Pathology Children's Memorial Hospital Northwestern University Medical School Chicago, IL 60614

Chakk S. Ramesha Department of Biochemistry Roche Biosciences 3401 Hillview Avenue Palo Alto, CA 94303

F. Rashid The Aga Khan University Depts. of Pharmacology and Physiology Stadium Road Karachi-74800, Pakistan 3500

Ramesh G. Reddy Oxford Biomedical Research Avon Industrial Drive Rochester Hills, MI 48309

Srinivasa T. Reddy University of Cali fomi a at Los Angeles Los Angeles, CA 90095

Bruno Robibaro Department of Infectious Diseases University of Vienna Waehringer Guertel 18-20 A-I090 Vienna, Austria Catherine M. Roche Department of Pharmacology Faculty of Medicine Chinese University of Hong Kong Shatin, New Territories, Hong Kong

Ian W. Rodger Department of Pharmacology Merck Frosst Centre for Therapeutic

Research Kirkland Quebec, H9H 3Ll Canada

Contributors

P. Roy Merck Frosst Centre for Therapeutic


Sheikh A. Saeed Depts. of Physiology and Pharmacology Aga Khan University Karachi-7480, Pakistan 3500

Yasushi Saitoh The 2nd Department of Internal Medicine Chiba University School of Medicine Chiba, Japan

Bengt Samuelsson Departments of Medical Biochemistry and


Takahiro Sato Department of Physiological Chemistry Graduate School Tokyo Medical and Dental University Yushima l-chome Bunkyo-ku Tokyo 113, Japan

Reiner Schaumann Department of Infectious Diseases University of Vienna Waehringer Guertel 18-20 A-1090 Vienna, Austria

Melvin Schindler Department of Biochemistry Michigan State University East Lansing, MI 48824-1224

Heike Schwende Biochemisches Institut c/o Klinik fUr Tumorbiologie Universitat Freiburg Breisacherstr. 117 D-79106 Freiburg, Germany

R. Seger Depts. of Membrane Research and

Biophysics The Weizmann Institute of Science Rehovot, Israel; FSP II Tumor Regulation DKFZ, Heidelberg D6900, Germany

Judith Senior Postgraduate School of Pharmacology University of Bradford Bradford West Yorkshire, BD7 1 DP United Kingdom

G.H. Shah The Aga Khan University

581

Depts. of Pharmacology and Physiology Stadium Road Karachi-74800, Pakistan 3500

Bukhtiar H. Shah Depts. of Physiology and Pharmacology Aga Khan University Karachi-7480, Pakistan 3500

Zhenzhen Shan Union Hospital Tongji Medical University Whan, 430030, P.R.C.

Rameshwar K. Sharma The Unit of Regulatory and Molecular

Biology University of Medicine & Dentistry of NJ School of Osteopathic Medicine 2 Medical Center Drive Stratford, NJ 08084

Rong-Nian Shen Departments of Medicine School of Medicine University of Maryland at Baltimore Baltimore, MD

Ke Shen The Institute of Chemical Toxicology 2727 Second Avenue Detroit, MI 48201

582

Kuo L. Shen Department of Surgery Tri-Serv. General Hospital National Def. Medical Center Taipei, Taiwan, R.O.C.

Tatsuya Shiina The 2nd Department of Internal Medicine Chiba University School of Medicine Chiba, Japan

Takao Shimizu Department of Biochemistry Faculty of Medicine The University of Tokyo Tokyo 113, Japan

Yasutsugu Shimonishi Institute for Protein Research Osaka University Suita Osaka 565, Japan

Yuanzheng Si Union Hospital Tongji Medical University Whan, 430030, P.R.C.

Daniel L. Simmons Department of Chemistry and Biochemistry Brigham Young University Provo, Utah 84602-4627

K. Skorey Merck Frosst Centre for Therapeutic


William Smith Department of Biochemistry Michigan State University East Lansing, MI 48824-1224

Oliver Smithies Department of Pathology University of N.C. at Chapel Hill Chapel Hill, NC 27599-7525

K. Soderstrom Oregon State University Corvallis, OR 97331

Stephen A. Spindler Oxford Biomedical Research Avon Industrial Drive Rochester Hills, MI 48309

T. Peter Stein Department of Surgery

Contributors

University of Medicine & Dentistry ofNJ School of Osteopathic Medicine 2 Medical Center Drive Stratford, NJ 08084

Hannelore Stender Institute of Biochemistry University Clinics (Charite) Humboldt Universitat Hessische Str. 3-4 10 115 Berlin, Germany

Jay C. Strum Glaxo Well come Inc. Research Triangle Park Alexander, NC 27709

Xiao-ming Sun Department of Pathology Children's Memorial Hospital Northwestern University Medical School Chicago, IL 60614

Hiroshi Suzuki Department of Biochemistry Tokushima University School of

Medicine Kuramoto-Cho Tokushima 770, Japan

Masaaki Suzuki Department of Experimental Pediatrics The University of Texas M.D. Anderson Cancer Center 1515 Holcombe Blvd Houston, TX 77030

Contributors

Karoly Szekeres First Institute of Pathology & Experimental

Cancer Research Semmelweis University of Medicine Budapest, Hungary

P. Tagari Merck Frosst Centre for Therapeutic


Hsin-Hsiung Tai Division of Medicinal Chemistry and


Yoshitaka Takahashi Department of Biochemistry School of Medicine The University of Tokushima Kuramoto-Cho Tokushima 770, Japan

Toshifumi Takao Institute for Protein Research Osaka University Suita Osaka 565, Japan

Yutaka Taketani Department of Biochemistry School of Medicine The University of Tokushima Kuramoto-Cho Tokushima 770, Japan

Fiona S.F. Tam Department of Pharmacology The Chinese University of Hong Kong Shatin New Territories Shatin, Hong Kong

Yasushi Tamura Sasaki Institute KyoundoHiratsuka Hospital 1-12 Sodegahama, Hiratsuka-Shi Kanagawa, 254 Japan

Jian-Zhen Tan

583

Department of Physiology and Medicine New York Medical College Valhalla, NY 10595

Xiao-di Tan Department of Pathology Children's Memorial Hospital Northwestern University Medical School Chicago, IL 60614

Michiharu Tanabe Department of Neurosurgery Tottri University 86 Nishi-Machi, Yonago, 683 Japan

Tadashi Tanabe National Cardiovascular Center Research

Institute Suita, Osaka 565, Japan

Chin-yu Tang Department of Dentistry University of Medicine & Dentistry ofNJ School of Osteopathic Medicine Stratford, NJ 08084

Dean G. Tang Department of Radiation Oncology Wayne State University Detroit, MI 48202

Ttakashi Terano The 2nd Department of Internal Medicine Chiba University School of Medicine Chiba, Japan

JozsefTimar First Institute of Pathology &

Experimental Cancer Research Semmelweis University of Medicine Budapest, Hungary

584

Raymond R. Tjandrawinata Department of Medicine University of California-San Francisco and Laboratory of Cell Growth (151 F) Veterans Affairs Medical Center San Francisco, CA

Larry W. Tjoelker ICOS Corporation 22021 20th Avenue S.E. Bothell, WA 98021

E. Di Tomaso The Neurosciences Institute 10640 John J. Hopkins Drive San Diego, CA 92121

Jozsef Tovari First Institute of Pathology & Experimental

Cancer Research Semmelweis University of Medicine Budapest, Hungary

Khai Tran Faculty of Medicine University of Manitoba 770 Bannatyne Ave. Winnipeg, Manitoba R3E OW3, Canada

Mohit Trikha Department of Radiation Oncology Wayne State University 431 Chemistry Building Detroit, MI 48202

Benjamin K. Tsang Department of Obstetrics & Gynaecology


Naoyuki Uchida Department of Dermatology Tokushima University 3-18-15 Karamoto-cho Tokushima, 770 Japan

Natsuo Ueda Tokushima University Department of Biochemistry Kuramoto-cho 3 Tokushima, 770 Japan

Naonori Uozumi Department of Biochemistry Faculty of Medicine The University of Tokyo Tokyo 113, Japan

L. Venance The Neurosciences Institute 10640 John J. Hopkins Drive San Diego, CA 92121

P. Vickers

Contributors

Merck Frosst Centre for Therapeutic Research

P.O. Box 1005, Pointe Claire-Dorval Quebec, H9R 4P8 Canada

Harold Vorbach Department of Infectious Diseases University of Vienna Waehringer Guertel 18-20 A-I090 Vienna, Austria

Contributors

Iwao Waga Department of Biochemistry Faculty of Medicine The University of Tokyo Hongo 7-3-1 Bunkyo-ku, Tokyo 113, Japan

ErikWalum Department of Cell Biology Pharmacia AB B i op harmaceuticals S-112 87, Stockholm, Sweden

Takashi Watanabe Department of Neurosurgery Tottri University 86 Nishi-Machi, Yonago, 683 Japan

Wenling Wei Center for Reproductive Medicine Union Hospital Tongji Medical University Whan, 430030, P.R.C.

Guenter Weigel Department of Cardiothoracic Surgery University of Vienna Waehringer Guertel 18-20 A-I090 Vienna, Austria

Jacobus P.J. van der Westhuizen Department of Dermatology Faculty of Medicine University of Medicine Univrsity of the Orange Free State Bloemfontein, South Africa 9300

A. Wetter holm

Department of Medical Biochemistry and Biophysics Karolinska Institutet S-171 77 Stockholm, Sweden

M.L. Wise Oregon State University Corvallis, OR 97331

Helen Wise Department of Pharmacology The Chinese University of Hong Kong Shatin New Territories Shatin, Hong Kong

Leo Duyvene de Wit Department of Anatomical Pathology Faculty of Medicine University of Medicine Univrsity of the Orange Free State Bloemfontein, South Africa 9300

Gert Wolf Pharmazeutisch-Chemisches Institut Universitiit Heidelberg 69120 Heidelberg, Germany

E. Wong Merck Frosst Centre for Therapeutic


Jason Wong Faculty of Medicine University of Manitoba 770 Bannatyne Ave Winnipeg, Manitoba R3E OW3, Canada

Patrick Y-K Wong Department of Cell Biology

585

University of Medicine & Dentistry ofNJ School of Osteopathic Medicine 2 Medical Center Drive Stratford, NJ 08084

Mo-Lam Wong Xing-Ya Pharmaceutical Co., Ltd Guangdong, China

David F. Woodward Depts. of Biological Sciences and


586

Huizhu Xia Union Hospital Tongji Medical University Whan, 430030, P.R.C.

Weilin Xie Depts. of Biological Chemistry &

Pharmacology Molecular Biology Institute Lab. of Structural Biology & Molecular

Medicine University of California at Los Angeles Los Angeles, CA 90095

Zhongming Xiong Union Hospital Tongji Medical University Whan, 430030, P.R.C.

Ji-Yan Xue Department of Cell Biology University of Medicine & Dentistry ofNJ School of Osteopathic Medicine 2 Medical Center Drive Stratford, NJ 08084

Kei Yamamoto Department of Biochemistry School of Medicine The University of Tokushima Kuramoto-Cho, Tokushima 770, Japan

Shozo Yamamoto Department of Biochemistry School of Medicine University of Tokushima Kuramoto-Cho, Tokushima 770 Japan

Chin-Yu Yang Department of Dentistry Tri-Serv. General Hospital Taipei, Taiwan, R.O.C.

Y.L. Yek Department of Phamacology College of Medicine National Cheng Kung University Tainan City, Taiwan 70101, R.O.C.

Takehiko Yokomizo Department of Biochemistry Faculty of Medicine The University of Tokyo Tokyo 113, Japan

Tanihiro Yoshimoto Department of Biochemistry School of Medicine

Contributors

University of Tokushima Kuramoto-Cho, Tokushima 770, Japan

M. Rita Young Research Service (151-Z2) Veterans Administration Hospital Hines, IL 60141

Uriel Zor Depts. of Membrane Research and


INDEX

AACOCF1,118 Acemethacin, 407 N-Acetylethanolamines, 335 N-Acetylimidazole, 2-3 Actin, 311, 313--314, 315---316, 317 Actinomycin 0, 35---36, 37, 38 Activin A, 243-248 Acute phase proteins, spaceflight and, 443--449 N-Acylphosphatidylethanolamine (NAPE), 335 Adenomatous polyps

Gardner's syndrome cell growth, NSAID regulation, 433-440

type 1/, PLA2 and, 115 Adrenergic-mediated effects, joint perfusion, 265---269 A549 cells

IL-I ~ regulation of Iipocortin, COX-2, and cPLA2,

249-253 15-LOX, intracellular localization. 27-31

A431 cells, 9-14, 33-39 AGN 191976,225,226,227,228 AGN 192093, 225, 226, 227, 229, 230 Agyria,362 AIDS. murine

Naturin-2 and, 545---548, 549 total body irradiation and, 451-457

Algal eicosanoids. 330-334 Allergy

5-LOX,27 PGE2 regulation of Band T cells, 237-240

al/~3 integrin activation state, 55---59 melanoma cells, 306, 307, 309

Alveolar macrophages, 281-287 4-Aminopyridine, 215, 216 Amphibians, 555---559 Anandamide

anandamide amidiohydrolase purification and characterization, 323--328

conjugated triene anandamide, biosynthesis and receptor affinity, 329-334

exogenous lipid activators of cannabanoid receptor, 335---340

macrophage release of AA, 341-346

Anandamide aminohydrolase, 336 Angiotensin 1/, 256 Antigen presenting cells, 237 APC, 43, 46, 48, 115 Apoptosis

ceramide-mediated, 145---149 development ofCNS, 362 Iipoxygenase role, 31, 405-409 peroxynitrite in HL-60 cells, 413--418

Aprotinin, 312 Arachidonic acid, see also specific en::ymes

anandamide-induced release from macrophage line. 341-346

hydroxamic derivatives as 5-LOX inhibito(s, 471-475

keloid composition, 518 myoblastic cell release, vitamin E and. 123-128 rat liver macrophage release

MTP-induced.485-489 PLA2 role in. 479-483

AP2 regulatory element. 13 Arachidonic acid lipoxygenases: see Lipoxygenases Arginyl reagents. 3 ,\ristolochic acid, 511 Arochlors, 295---302 Arteriosclerosis obliterans, 400 Aspirm

and colorectal cancer, 437 eicosapentaenoic acid and, 400 PGS-I inhibition in mast cells, 63~4

Assays PAF, 459-464 prostaglandin endoperoxide H synthase, 521-524

Astrocyte cells, primary, 236 Atherogenesis

eicosapentaenoic acid mechanism of action, 399-403

lipoprotein effects in PKC-COX in macrophages, 93-97

15-LOX,27 ATP, 211,275---276 A TP synthase, 215 A TP transcription factor. 62

587

588

Atrial natriuretic factor, 272-276 A23187, 107, 108

AA release in cardiac myoblasts, 124 in liver macrophages, 479--483

15-LOX induction, 27-31 PLA2 differential activation in keratinocytes,

117-121 platelet aggregation, dopamine potentiation of,

537-540 reactive oxygen species formation, 293 THP-I cell differentiation, 491-495

Autonomic motor neurons, prostacyclins and, 211

BAY u3405, 225, 226, 228, 229 B cells, 237-240 Bcl-2, 147-149 BEL,IOI Benzodioxane-prostacyclin, 215 Bestatin, 3, 5 BHPP, 13-14,407,408 Birth: see Parturition Blood cells. see also Bone marrow cells; Hematopoie

tic cells; Platelets; White blood cells 12-LOX distribution. 15-19 POEz regulation of Band T cells, 237-240

Blood flow, see also Vascular tissue joint tissue, 265-269 pulmonary, 561-566

BMS-180,291,479 BMY 22389, 261-263 BMY 42393, 211,213-214.261-263 BMY 45778, 211,213-214,216,261-263 Bone, osteoclast formation, 383-386 Bone marrow cells

12-LOX, platelet-type, 16-17, 19 osteoclast formation, 383-386

Bradykinin, 292-293 Brain

PAF receptor, 357-362 POHS-2 in Alzheimer's disease, 171-176

BRCAI, 45, 49 Breast cancer, synthesis of eicosanoid-like compound,

179-183 Breast epithelial cells, pesticide effects, 295-302 2,3-Butanedione, 3 Butanoic acid derivatives, COX inhibition, 77-78

Calcium AA release in rat liver macrophages, 479 N-acetylethanolamines and, 336-340 EOF activation of 12-LOX, II guanylate cyclases, 276-277 macrophage activation, 376-377 MAP kinase, PLAz' and reactive oxygen species ac

tivation in keratinocytes, 289-293 mast cell activation, 107 parathyroid hormone effects in bone, 383-386

Calcium (cont.)

PAF receptor mediated changes, 360-361 platelets

dopamine potentiation, 537-540 platelet signal transduction, 531-534

Index

THP-I cell differentiation, 491-495 Calcium-activated K channels, 211 Calcium-dependent lipid binding proteins (CsLB),

291 Cannabinoid receptors: see Anandamide Captopril,5 N-(Carboxyalkyl)maleimides, 79-84 Carcinogenesis: see Tumor biology Carcinoma cyclase, 272 Cardiac myoblasts, 123-128 Carprofen, 407 Cathepsin B, 306 CD antigens, 282, 491-495 C/EBP family, 142-143 Cell adhesion: see Cell-cell and cell-ECM interactions Cell-cell and cell-ECM interactions

apoptosis. 405 fibroblast-mast cells for POEz production, 53-65 melanoma metastatic cascade. 303-309 tumor cells, 55-59

Cell cycle, ceramide effects on apoptosis, 148-149 cell cycle progression, 421-430

Cell differentiation: see Differentiation Cell growth

apoptosis, see also Apoptosis lipoxygenase role, 405-409 peroxynitrite in HL-60 cells, 413-418

ceramide antiproliferative effects, 145 inhibition of

antitumor prostaglandin modulation by MRPlGSX pump, 387-390

linolenic acid metabolism of cells overexpressing Erbb-2IHER2 oncogene, 393-397

vascular effects of eicosapentaenoic acid, 399--403

lipid second messenger role, 421-430 ovarian granulosa cells, 509-513 POE2 and

PTH mediation, 383-386 regulation, 169

THP-I cell differentiation, 491-495 Cell membranes: see Membranes; Receptors; Signal

transduction Ceramide

apoptosis, 145-149,405 cell cycle progression, 425, 427-429

Cerebral vasospasm, 12-HPETE in, 21-25 c-fos

POEz and, 434 prostate cancer cell growth, 169

COP-28238, 159,503-506 Chelerythrine, 533

Index

Chemical syntheses. 7-oxabicyclo[2.2.1] heptane derivatives of TXA2• 497-501

Cholecalciferol metabolites. THP-I cell differentiation, 491-495

Chondrocyte cultures, COX-2 inhibitors, 160 Cicaprost

prostacyclin receptor activation, 211-212 relative potency. neuronal stimulation. 215. 216

Ciliary muscle cell culture. 231-232. 233, 235 c-jun

PGE2 and, 434 PGS-2 induction. 62 prostate cancer cell growth, 169

Clinical studies eicosapentaenoic acid mechanism of action, 399-403 Gardner's syndrome cell growth, NSAID regulation,

433-440 murine AIDs cured by total body irradiation.

451-457 parturition. plasma PAF changes. 551-553 space flight, C-peptide and PGE2 activity during,

443-449 Cloning

leukotriene B4 12-hydroxy-dehydrogenase. 151-156 12-LOX, 36-37 LTB4,151-156 PAF receptor gene. 347-354 PGS-I/COX-2.61-62 PLA2, murine, 109-115

Clotrimazole. 259 cMet, 296, 300 c-myc.387 Cobra venom. 106 Colon. BMY 42393 action. 211, 213-214 Colorectal cancer

integrins, 56 NSAIDS and Gardner's syndrome cell growth.

433-440 Compound 48/80, 107, 108 Conjugated triene anandamide. 329-334 COX-I /PGHS-I. see also Prostaglandin synthases

granulosa cells, 512 mutant mouse, 87-91 species differences in pharmacology. 67-71

COX-2/PGHS-2, see also Prostaglandin synthases bone metabolism, 384. 385 function and regulation of, 61 Gardner's syndrome cells, 436. 437, 439-440 gene expression

IL-I p regulation in A549 cells. 249-253 NFkB and NF-IL6, 185-189 PGE2 up-regulation, 163-169 TNFo.-dependent, 185-189

inhibitors inandone derivatives, 503-506 indolealkanoic acids, 73-78 possible anti-inflammatory agents, 157-160 species'differences in pharmacology. 67-71

COX-2/PGHS-2 (cont.)

mutant mice, 131-137 gastric ulceration, 136 inflammation in. 134-136, 137 renal pathology. 132-134, 135

ovarian granulosa cells, 509-513 radicicol and, 281-287 regulation of

inhibitors as potential therapeutic agents. 157-160

PGE2 up-regulation of, 163-169 C-peptide during spaceflight, 443-449 cPLA2, 249-253 Cyclic AMP

lymphocyte development, 238, 239, 240 platelet signal transduction, 534

589

prostacyclin mimetic effects on neutrophil function, 262-263

Cyclic AMP response element binding protein (CREB), PGS-2 induction, 62, 63

Cyclic AMP response element (CRE), COX-2 gene, 139, 140, 142, 143-144, 185-186

Cyclic GMP, plasma membrane guanylate cyclase. 271-277

Cyclins, 387-388 Cycloheximide. 64 Cyclooxygenases: see COX-IIPGHS-I; COX-

2/PGHS-2; Prostaglandin synthases Cytokines

alveolar macrophages. radicicol and. 281-287 apoptosis,405 bone changes. 383. 384 in breast cancer cell line, 179-183 and COX-2. 185-189 dietary fats and. 377 integrin o.llP3 regulation, 56 lymphocyte regulation by PGE2• 237-240 Raf-I.422 receptor. melanoma cells, 308 renal cytochrome P450-dependent eicosanoids.

257-260 sPLA2 as, 108

Cytoskeleton melanoma cells. 12-LOX products and.

304-305 protein phosphatases and. 311-317

Cytosolic PLA2 differential activation in keratinocytes, 117-121,

289-293 myoblast agonist-induced AA release, 124-125

Cytotoxicity LPS and MTP-Pe-induced, 485-489 rat liver macrophage activation, 485-489

DAG: see Diacylglycerol DAPHI, 10, 12, 13 DCC gene, 43. 46-48. 49, 50 DDT, 295-302

590

Development CNS, 362 TH2 lymphocytes, 238

Dexamethasone, 64 with activin A, 245, 247 and ceramide, 145, 146, 148 IL-I ~ stimulation of AA release from A549 cells,

252,253 Diacylglycerol,421

AA release in rat liver macrophages, 479--483, 485--489

and ceramide effects on apoptosis, 146-147, 148 platelet signal transduction, 531 vitamin E and, 123

Dichlorobenzimidazole riboside, 35-36, 37, 39 Diclofenac, 159,407 Dietary fats

eicosapentaenoic acid mechanism of action, 399-403 keloid fibroblast effects, 515 macrophage tumoricidal capability, 372, 375-376,

377 prostate cancer cell growth, 169

Differentiation activin A and, 243-248 ceramide and, 145 keratinocyte, 290 THP-I cells, 491--495

Diflunisal,407 5(S),12(R)-DiHETE,555-559 Dihydroxy-vitamin D

bone changes, 383-386 and ceramide, 145, 146

7,7-Dimethyleicosadienoic acid, 511 Dithiothreitol,64, 118 D-NAME,211 DU 145 cells, 46--48 Dup-697, 73, 159

ECM: see Cell-cell and cell-ECM interactions EGF: see Epidermal growth factor Eicosapentaenoic acid

breast cancer cell synthesis of eicosanoid-like compound, 179-183

vascular cell anti-proliferative action, 399--403 Eicosatetraynoic acid (ETY A), 258 Endometrial cell PAF receptor regulation, 200-201 Endothelial cells

inflammatory stimuli, 237 integrin all~3, 56 prostaglandin-endoperoxide synthase-2 gene regula

tion,139-144 teicoplanin effects, 525-529

Endotoxin: see LPS Eosinophils

12-LOX distribution, 16-17, 19 15-LOX,27-31

Epidermal growth factor (EGF), 249 COX-2 up-regulation by PGEz, 163-169

Index

Epidermal growth factor (EGF) (cont.)

DDT and arochlor effects in breast epithelial cells, 296,300-301

keratinocyte proliferation, 289-293 linolenic acid metabolism

in cells overexpressing Erbb-2IHER2 oncogene, 393-397

signal transduction, 319-322 and 12-LOX in A431 cells, 9-14, 33-39 renal cytochrome P450-dependent eicosanoids, 256

Epidermal keratinocytes: see Keratinocytes Epoxyeicosatrienoic acids (EETS)

cytochrome P450-dependent eicosanoids, 255, 258 pulmonary vasodilation, 561-566

c-erb2, 296, 298-299 Erbb-2IHER2, 393-397 ERK-I and ERK-2

AA release in rat liver macrophages, 481 PLA2 activation, 289-293

Erythropoiesis, 15-LOX, 27-31 Estrogen, PAF receptor regulation in endometrial

cells, 200-201 7-Ethoxyresorufin, 259 ETYA,407 Extracellular matrix, see a/so Cell-cell and cell-ECM

interactions apoptosis, 405 melanoma metastatic cascade, 303-309

Extracellular matrix proteins, 55

F-actin in tumor cells, 311, 313-314, 315-316, 317 FAK kinase, melanoma cells, 303, 306, 308 Familial adenomatous polyposis, 433--440 Fas ligands, and ceramide, 145, 146-147. 148 Fatty acids

apoptosis, 406 eicospentaenoic acid mechanism of action, 399--403 hydroxamic derivatives as 5-LOX inhibitors,

471--475 keloid composition, 515-520 PLAz differential activation in keratinocytes.

117-121 signal transduction in macrophages, 371-377

Fertility, COX deficient mouse, 90 Fibroblast growth factors, 56, 406 Fibroblasts

inflammatory stimuli, 237 keloid, 515-520 PGS-2 expression for prostaglandin production.

62--63,64 reactive oxygen species, 292

Fibronectin apoptosis, 405 melanoma cells, 306, 307

Fish oils. 372, 377. 399--403 Flosulide. 73 Flufenamic acid, apoptosis, 407 Fluprostinol, 235

Index

Flurbiprofen COX-2 mRNA accumulation. 166-167. 168 Gardner's syndrome cells. 437, 438 human versus rat COX-2, 69, 70 PGE2 effects on prostatic carcinoma cell growth, 165

Flusolide. 70 Follicular dendritic cells, 237 N-Formyl-methionyl-Ieucyl-phenylalanine, 261. 262 FP receptor. 231-236 Free radicals. activation in keratinocytes, 289-293 Friend virus, 451-457. 545-548 Frog tissues, L T A4 conversion in, 555-559 Fumonisin B" 429

GAL4 transcription factor, 62 Gardner's syndrome colorectal cancer cell growth.

433-440 Gastrointestinal tract

COX-I orCOX-2 mice. 134-136. 137 COX-deficient mouse, 87-91 indanone derivative safety, 503 12-LOX distribution, 18 neuronal stimulant action of prostacyclin mimetics,

211-214 NSAID side effects, 15..7 PAF

interactions with NO, PLA2, eicosanoids, and NO synthase. 365-368

necrotizing enterocolitis, role in, 379-382 PLA2 expression in. 114, 115

Gene expression ceramide-mediated apoptosis, 145-149 cytokines and

in breast cancer cell line. 179-183 TN Fa-dependent induction of COX-2. 185-189

growth factor. in breast epithelial cells, 295-302 integrin activation. 55-59 12-LOX.191-195

EGFR and 12-LOX regulation of, 9-14. 33-39 and multiple tumor suppressor genes in prostate

cancer, 4-1-50 LTB4 cloning and mutagenesis. 151-156 PAF receptor, 197-203 PGHS-I/COX-l gene disruption, 87-91 PGHS-2/COX-2, 61-65

in Alzheimer's disease, 171-176 inhibitors as potential therapeutic agents, 157-160 PGE2 up-regulation of, 163-169 PGHS-2 deficient mice, 131-137 regulation of, 61-65 in vascular endothelial cells, 139-144

PLA2S in keratinocytes, 117-121 prostaglandin synthesis in ovarian granulosa cells,

509-513 Gene structure

PAF receptor gene, 347-354 prostanoid receptors, site-directed mutagenesis,

205-209

Genisteine. 247. 248 Germinal vesicle breakdown (GYBD). 427-42g Glycerophospholipids.421 GM-CSF.245 Gonadal tissues

activins.243 ceramide as intracellular in ovary. 421. 425.

427-429

591

ovarian granulosa cells. 185. 509-513 prostacyclin/prostacyclin mimetic stimulation of vas

deferens. 214-216 gp78. melanoma cells. 308. 309 G-protein coupled receptors

cannabinoid receptor, 329 EGF signal transduction. 320. 321 melanoma cytokine receptor. 308 Ra~I.422-425,426

Granulosa cells, 185, 509-513 Growth regulation: see Cell growth Growth regulators. see also Cytokines; 5pecijic reglilators

activin A, 243-248 apoptosis, 405 breast cancer cell synthesis of eicosanoid-like com

pound. 179-183 and ceramide. 145. 146 eicospentaenoic acid and vascular smooth muscle.

403 integrin all~3. 56. 57. 58. 59 ovarian granulosa cell response to TGF-a. 509-513 PGE2 as, 164

GTPase activating protein. EGF signal transduction, 320,321

Guanylate cyclase, 271-277 intracellular mechanisms of regulation. 276-277 natriuretic factor receptor. 273-276

Heart. vitamin E enhancement of AA release in car-diac myoblasts. 123-128

H-89.263 HEL-30 cells. 117-121 Hematopoietic cells

activins and. 243-248 integrin all~3. 55-56 12-LOX.15-19 15-LOX, 27-31 osteoclast formation. 383-386

HETEs, see also specific enzymes cytochrome P450-dependent eicosanoids, 255, 256.

257 5-HETE, granulosa cells, 511 12-HETE, melanoma cells. 304-305, 307, 309 12(S)-HETE,405-409

integrin alI~3 regulation, 56, 59 tumor suppression gene regulation in prostate can

cer, 46-48, 50 15-HETE'

apoptosis, 406 COX-2 acetylation by aspirin, 132

592

Histamine, mast cell activation, 105-108 HL-60 cells, 145

apoptosis, 413---418 differentiation, 491

13-H(p)ODE, 319-320, 321,322 HODEs, 477---478; see also specific enzymes

13S-HODE, 15-LOX and, 28 12-HODE, melanoma cells, 304-305 linolenic acid metabolism of cells overexpressing

Erbb-2IHER2 oncogene, 393 Hormone response element, PAF receptor regulation,

201,202 HPETEs: see specific enzymes HT-29 cells, 407 HUCM cells, 235236 Human erythroleukemia cells (HEL), integrin alllB,

55~56,57,59

Human immunodeficiency virus, 357 Humans

cyclooxygenase pharmacology, 67~71 thromboxane receptor mediated action in

myometrium and umbilical artery preparations, 219-230

la antigen expression, macrophage, 375 I-BOP, 225, 226, 227 Ibuprofen

apoptosis, 407 human versus rat COX-2, 69, 70

IFN-y: see Interferon-y IgE, B cell production, 238, 239-240 IgE receptors, mast cells, 105-108 IL-I

activin A and, 246 bone changes, 383, 384, 385 integrin all~3 regulation, 56 macrophage antitumor activity, 371 Th2 lymphocyte development, 238

IL-I a, PTK inhibitors and, 281 IL-I~

bone metabolism, 384 chondrocyte cultures, 160 lipocortin, COX-2, and cPLA2 regulation by in

A549 cells, 249-253 PTK inhibitors and, 281, 283, 284, 287

IL-4 isotype switching, 239 15-LOX induction, 27~30, 31 Th2 development, 238

IL-5,238 IL-6

bone metabolism, 383, 384 breast cancer cell synthesis of eicosanoid-like com-

pound, 179~183 IL-IO,238 IL-II,384 IL-12,238 IL-13,239 Iloprost, 185, 211 ~217

Index

Immediate-early genes, COX-2 classification as, 168 Immunoelectron microscopy, 15-LOX, 27~31 Immunohistochemistry, 12-LOX, platelet-type, 19 Inandone derivatives, COX-2 inhibition, 503~506 Indolealkanoic acids, COX-2 inhibitors, 73~78 Indomethacin, 159

apoptosis, 407 bone metabolism, 383 cyclooxygenase pharmacology, humans versus rats,

69-71 joint perfusion, 265~269 renal cytochrome P450-dependent eicosanoids, 259

Inflammation COX-2 in

COX-2 deficient mice, 89~90, 134-136, 137 inhibitors, 157~160 role of, 132

gut, mechanisms of, 365~368 IL-I ~ regulation oflipocortin, COX-2, and CPLA2

in A549 cells, 249-253 joint tissue, prostaglandin and NO effects on blood

flow, 265~269 5-LOX,27 LTA4 , active site of LTA hydrolase, I-{) mast cells, secretory PLA2 effects, I 05~1 08 prostacyclin mimetics, effect on neutrophils,

261~263

prostanoids activin A effects, 243~248 PGE2 regulation of Band T cells, 23 7~240

renal cytochrome P450-dependent eicosanoids, 255~260

spaceflight and, 443---449 Inositol-I,4,5-triphosphate, platelet signal transduc

tion,531 Insulin-like growth factor, 405 Integrins

apoptosis, 405 melanoma cells, 306, 307, 309 tumor cells, 55-59

Interferon-y,455 breast cancer cell synthesis of eicosanoid-like com-

pound, 179-183 and ceramide, 145, 146 integrin all~3 regulation, 56 macrophage activation, 371 macrophage antitumor activity, PAF-induced, 377 Th2 lymphocyte development, 238

Interleukin-l converting enzyme, apoptosis, 405 Interleukins: $ee IL-I, etc. Intestine: see Gastrointestinal system Intracellular localization: see Subcellular localization Intracellular signaling: see Signal transduction Invasion: see Metastatic cascade Iodoacetate, 34, 36 Ion channels, see also Calcium

IP receptor agonist action, 211 renal cytochrome P450-dependent eicosanoids, 256,

259

Index

Joints blood flow and inflammation. 265-269 COX-2 inhibitor effect on articular chondrocyte cul

tures. 160 1744,341-346 Jun kinase. 62. 289, 290

Keloids, 515-520 Keratinocytes

12-LOX distribution, 18--H, 33, 36 MAP kinase activation, 289--293 PLA2 synthase expression in, 117-121

a-Keto-~-amino-ester (compound IV), 6 Kidney

COX-2 deficient mice, 132-134, 135 cytochrome P450-dependent eicosanoids, 255-260

Kinins, P450-derived AA metabolite and, 260 Klep5 cells, 235

L-745,337, 73-74,157-160 L-748,780,76 Labor and delivery: see Parturition Langerhans cells, 237 LDL: see Low-density lipoproteins Leukemia inhibitory factor, 384 Leukotriene A4

active site of Leukotriene A4 hydrolase, I--{) enzymatic conversion in frog tissues, 555-559

Leukotriene 8 4 cloning and mutagenesis. 151-156 Leukotrienes

granulosa cells, 511 vitamin E and, 123

Leupeptin. 312 Lewis lung carcinoma

naturin-2. 541-548 protein phosphatases and. 311-317

Linoleic acid. 406 HODEs, role and detection of. 477--478 keloid composition. 518. 520 keratinocyte effect. 290 15-LOX and. 28 prostate cancer cell growth. 169

Linoleic acid metabolism in cells overexpressing Erbb-2/HER2 oncogene.

393-39 and EGF signal transduction. 419--322

Lipid mediators growth regulation and cell cycle progression.

421--430 ceramide, cell cycle progression, 425, 427--429 Raf-I kinase-phosphatidic acid interaction.

422--425,426 macrophage antitumor activity, 371 platelet signal transduction, 531-534 signal transduction in macrophages, 371-377 vitamin E and, 123

Lipids, endogenous. cannabinoid receptor activation, 335-340

593

Lipocortin, IL-I ~ regulation in A549 cells. 249-253 Lipopolysaccharide (LPS)

chondrocyte cultures. 160 GI system. mechanisms of inflammation and protec

tion. 365-368 macrophage acti vatlOn. 371

arachidonic acid release. 479--483 muramyl peptides and. 485--489 PAF receptor expression. 351-353 radicicol and, 281-287

necrotizing enterocolitis. 379--382 PAF receptor regulation, 200 PLA2 expression. 114. 115 THP-I cell differentiation. 491--495 TPA, COX-2 gene expression. 140--141

Lipoproteins. PKC-COX effects in macrophages. 97 Liposomes, 422. 485--489 5-Lipoxygenase activating protein (FLAP). 27 Lipoxygenases

anandamide as substrate of 12- and 15-LOX. 327 apoptosis. 405--409 cancer/tumor biology

EGF in A431 cells, 9--14, 33-39 EGF receptor TK and 12-LOX regulation of 12-

LOX expression, 9-14 integrins, 55-59 prostate cancer. 33-39

in melanoma. 304-308 leukotriene A4 hydrolase active site, I--{) 5-LOX.27

apoptosis. 407 inhibition by hydroxamic derivatives of FA,

471--475 12-LOX.21-25

apoptosis. 407. 408 catalytic properties. 191-195 EGF receptor in A431 cells. 33-39 EGF receptor tyrosine kinase and. 9-14 gene expression. 9--14.191-195 localization and distribution. 15-19

15-LOX localization in mammalian cells, 27-31 preferential oxidation of human LDL subfraction,

465--469 melanoma signaling pathways, 304 vascular system, 12-HPETE in pathogenesis of cere-

bral vasospasm, 21-25 Liver macrophages, 479--483 L-NAME.211 L-NNA,561-566 Loss of heterozygosity, in prostate cancer. 42--43. 44.

45.46--48 Low-density lipoproteins (LDLs)

eicosapentaenoic acid mechanism of action. 40 I 15-LO X ox idation of. 465--469 PKC isotype expression via PGHS in P388D 1 cells.

93-97 LPS: see Lipopolysaccharide

594

Lung, rabbit, 561-566 Lung cyclase, 272 Lymphocytes

apoptosis, 406 PGE2 regulation ofB and T cells, 237-240

Lysophosphatidyl serine, mast cell activation, 107 Lysophospholipids, granulosa cells, 511

Macrophages, 183 alveolar, radicicol and, 281-287 anandamide-induced AA release, 341-346 oxidized LDL effects on PKC in P388d, cells, 93-

97 PAF

receptor expression, 351-353 tumoricidal response, 371-377

PGE synthesis, 237 PGS-2 expression for prostaglandin production,

62--63 PLA2

and AA release, 479--483 calcium independent, 99--103

release of eicosanoids, TNF-a, and NO, 485-489 THP-I cell differentiation, 491--495

Manoalide, 64 MAP kinases

AA release in rat liver macrophages, 479, 480, 481, 482

activation in keratinocyte line, 289--293 EGF signal cascade, 319, 320 radicicol and, 281, 286-287 Raf-I-PA interaction and, 425, 426

Marine algae, 33{}-334 Mast cells

activated, secretory PLA effects, 105--108 PGS-I distinct from PGS-2 in, 63--64 supernatant induction of PGE2 production in fi-

broblasts, 65 MBP kinase, 291-292 MCC, 46, 48--49 MDM2 gene, 46--48 Mefenamic acid, 407 Megakaryocytes

activins and, 243 integrin allJ33, 55--56 12-LOX distribution, 16-17, 19

Melanomas integrin allJ33, 56 metastatic cascade, invasion mechanism, 303-309

Membrane-associated protein kinases: see MAP kinases

Membranes 15-LOX association, 27-31 phospholipids, sPLA2 and, 107 plasma membrane guanylate cyclase, 271-277

Metastatic cascade integrin activation, 55--59 protein phosphatases, 311-317

Methylsulfones, 73-74 Microglia, PAF receptor, 347-354 Microsatellite sites in prostate cancer, 43--44 Microsomal localization of 12-LOX, 34-37 Miller-Dieker lissencephaly, 362 Mismatch repair deficiency, 43 Mitochondria, 15-LOX and, 3{}-31

Index

Mitogen induced prostaglandin production, PGS-2 re-quirements, 63

6-MNA, human versus rat COX-2, 69, 70 Molt-4, 145 Monocytes

15-LOX, intracellular localization, 27-31 THP-I cell differentiation, 491--495

Motility, melanoma cells, 306 Mouse, COX-deficient,87-9I, 131-137 MRPIGS-X pump, 387-390 MTP-PE, liposome encapsulated, 485--489 Muramyl peptides, liver macrophage activation,

485-489 Mutagenesis, site-directed, 205--209 Mutator phenotype, 43--44, 49 myc, 387 Myelin basic protein, 291 Myoblasts, cardiac, 123-128 Myometrium, 219, 221-223, 226

NADP binding domains, leukotriene B4 12-hydroxydehydrogenase, 151-152, 154-156

NADPH/NADH, cytochrome P450-dependent ei-cosanoids, 255

Naproxen, 159 Natural killer cell activity, 182 Naturin-2, 541-548 NDGA,407 Necrotizing enterocolitis, 379--382 Nerve growth factors, and ceramide, 145, 146 Neuronal cells/tissues, see also Brain

activins, 243 FP receptor, 233 guanylate cyclases, 276-277 prostacyclin mimetics and, 211-217

Neutrophils prostacyclin mimetic effects, 261-263 vitamin E effects, 123

NF-IL6, COX-2 gene regulation, 185--189 NF-KB

COX-2 gene, 139, 143, 185--189 12-LOX gene, 13-134 PAF receptor gene, 199,202

Niflumic acid, 407 Nimesulide, 70, 73 Nitric oxide (NO)

activin A and, 243-248 apoptosis in HL-60 cells, 413--418 and joint perfusion, 265--269 macrophage release, LPS and MTP-PE mediated,

485-489

Index

Nitric oxide (NO) (conI.) NO synthase

cicaprost and, 211 G\ system, mechanisms of inflammation and pro

tection, 365-368 PAF interactions in gut, 365-368

PAF interactions in gut, 365-368 vasodilation in rabbit lung, 561-566

NMDA receptors, 361 Non-adrenergic, non-cholinergic (NANC) nerves, 211 Noradrenaline, 212-213, 214-216 NS-398, 63, 64, 70, 159 NSAJDS

apoptosis, 407 COX-I effects. 132 COX-2 mRNA accumulation, 166-167, 168 COXs, human versus rat, 67-71 Gardner's syndrome colorectal cancer cell growth,

433-440 indanone derivatives, 503--506 indolalkanoic acid COX-2 inhibitpr, 73--78 joint perfusion, 265-269 PGE2 effects on prostatic carcinoma cell growth, 165 PGS-2 inhibition, 63

N-substituted maleimides, 79-84 N-terminal jun kinase. 289, 290 N-3 fatty acids, signal transduction in macrophages,

371-377 Nuclear factor for IL-6 (NF-IL6). 139, 143 Nuclear factor-kB: see NF-KB

Obstetrics: see Parturition Okadaic acid. 311. 312, 315, 316, 317 Omega unsaturated fatty acids, 399-403 Oncogenes/proto-oncogenes, 290; see also specific

oncogenes antitumor prostaglandins aAd, 387-390 apoptosis, 405 c-mos, oocyte maturation, 427 linolenic acid metabolisfn of cells overexpressing

Erhh-2IHER2,393--397 PGE2 and, 434 PGS2 induction, 62 prostate cancer cell growth, 169 Raf-I kinase-phosphatidic acid interaction,

422-425,426 Oocyte maturation, ceramide and, 421, 425, 427-429 Osteoclast formation, 383--386 Osteogenic cells, COX-2 regulation, 185-189 Ovaries

granulosa cells, 185, 509-513 COX deficient mouse, 90

7-0xabicyclo[2.2.1] heptane TXA2 derivatives, 497-501 Oxytocin, 243

p21 induction of by antitumor prostaglandins, 387-390 prostate cancer, 44, 45

p21 {ras}, 290, 422

p24,276 p53.46,49.451-457

595

Gardner'S syndrome cells. NSAIDS and, 436. 437 in prostate cancer, 42-43

p53/56. 281-282. 285-286. 287 P388D, cells

oxidized LDL effects on PKC. 93-97 . PLA2,99-103

PAC-I adhesion of tumor cells to, 57, 58. 59 melanoma cells, 306. 307

PACAP, 211 Pacemaker cells. 211 PAF: see Platelet activating factor Palmitoyl trifluoromethyl ketone (PACOFJ ). 102 Paneth cell-specific growth factor modulation. 114 Parathyroid hormone

osteoclast formation, 383-386 renal cytochrome P450-dependent eicosanoids, 256

Parturition COX deficient mouse, 90 plasma PAF changes during, 551-553

PCR: see Reverse transcriptase-PCR PDI53035,12-13 PDGF: see Platelet-derived growth factor Perinatal physiology: see Parturition Perlecan, melanoma metastatic cascade, 304 Peroxynitrite

apoptosis, 413-418 H L-60 cell apoptosis. 413-418

Pesticides, 295-302 PGD, PGE. etc.: see Prostaglandin D, etc. PGH synthases: see COX-I/PGHS-I; COX-2/PGHS-

2; Prostaglandin synthases Pharmaceuticals

conjugated triene anandamide, biosynthesis and receptor affinity. 329-334

hydroxamic derivatives of fatty acids as 5-LOX inhibitors, 471-475

inandone derivatives, 503-506 7-oxabicyclo[2.2.1] heptane derivatives of TXAo,

497-501 -r, 1 O-Phenanthroline. 5 Phorbol esters

AArelease in rat liver macrophages, 479-'-483 in rat heart myoblasts. tocopherol enhancement

of,123-128 and activin A effects, 246-247 and ceramide effects on apoptosis. 146-147, 148 reactive oxygen species formation, 293 THP-I cell differentiation, 491-495 TPA

COX-2 gene expression, 14~141 COX-deficient mouse, 89-90 PAF receptor regulation, 200 PLA2 differential activation in keratinocytes,

117-121 tumor cell adhesion, 57, 59

596

Phosphatases: see Protein phosphatases Phosphatidic acid

Raf-I kinase interaction, 422--425, 426 vitamin E and, 123

Phosphatidylinositol-3-kinase, 531-534 Phospholipase A, AA release in rat liver macrophages, 479 Phospholipase A2

AA release in rat liver macrophages, 479--483 apoptosis, 405--406 calcium-independent function in P388D cells,

99-103 GI system, mechanisms of inflammation and protec-

tion, 365-368 keratinocyte expression of, 117-121 and macrophage release of arachidonate, 479--483 mast cell production of PGE2, 64, 65 PAF interactions in gut. 365-368 prostaglandin synthesis in ovarian granulosa cells,

509-513 secretory, effects on activated peritoneal mast cells,

105-108 THP-I cell differentiation, 491--495 type II, cloning, 109-115

Phospholipase Az synthase gene expression in keratinocytes, I I 7-12 I

Phospholipase D, 421,422,425,426,427 COX-I gene disruption in mice, 87-91 oxidized LDL stimulation of PKC expression in

P388D cells, 93-97 vitamin E activation of AA release in cardiac

myoblasts,123-128 Phospholipids, mast cell activation, 107 PhXa85, 231,235,236 PKA (protein kinase A), 311-317 PKC: see Protein kinase C PLA: see Phospholipase A Plasma membrane guanylate cyclase, 271-277 Plasma membrane phospholipids, sPLA2 and, 107 Plasminogen activator, granulosa cells, 509, 513 Platelet activating factor (PAF)

assay, radioreceptor, 459--464 endometrial cell, 200--20 I gut

interactions with NO, PLA2, eicosanoids, and NO synthase, 365-368

necrotizing enterocolitis, role in, 379-382 macrophages

receptor expression, 351-353 tumoricidal response, 371-377

during parturition, 551-553 receptor

brain, 357-362 cloning and characterization, 347-354 gene structure and regulation, 197-203 macrophage, 351-353

Platelet activating factor acetyl hydrolase, 381 Platelet-derived growth factor, 320

apoptosis, 405 integrin allf33 regulation, 56

Index

Platelets BMY 45778,211 dopamine potentiation of A-23187 mediated aggre-

gation,537-540 eicosapentaenoic acid mechanism of action, 399 integrin allf33, 55-56 12-LOX, 16--17, 19,33,191-195 PLA2 expression, species differences, 115 signal transduction, agonist mediated, 531-534 vitamin E effects, 123

Platelet-type 12-LOX , 15-19 PMSF,312 Polyenoic fatty acid isomerase, 330--334 Polymerase chain reaction-SSCP, in prostate cancer,

43,44,45 Potassium channels, renal cytochrome P450-depend-

ent eicosanoids, 256, 259 Pregnancy: see Parturition Progesterone, 421, 425, 427--429 Propanoic acid derivatives, COX inhibitors, 77, 78 Prostacyclin mimetics

neuronal stimulant actions, 211-217 neutrophil effects, 261-263

Prostacyclin (PGI2), 525 Prostacylin receptors

neuronal stimulant actions, 211-217 prostacyclin mimetic actions, 211 site-directed mutagenesis. 205-209

Prostaglandin D2, rat liver macrophage activation, 485--489

Prostaglandin E2 apoptosis, 406--407 bone changes, 383-386 bone metabolism, 383 COX-2 up-regUlation, 163-169 Gardner's syndrome cells, 438--439 granulosa cells, 511 keratinocyte differentiation, 290 and parathyroid hormone effects in bone, 383-

386 protein phosphatases in tumor cells, 312 rat liver macrophage activation. 485--489 during spaceflight, 443--449 THP-I cell differentiation, 491--495

Prostaglandin F 2a' metabolic responses to, 231-236

Prostaglandins apoptosis, 407 FP receptor-mediated response in cultured cells,

231-236 Prostaglandin (endoperoxide) synthases (PGHS), see

also COX-I/PGHS-I; COX-2/PGHS-2 apoptosis, 406 assay, 521-524 gene expression of PGHS-2

in Alzheimer's disease, 171-176 function and regulation of, 61-{i5 PGHS-2 deficient mice, 131-137 in vascular endothelial cells, 139-144

Index

Prostaglandin (endoperoxide) synthases (PGHS) (cont.) inhibitors

indolalkanoic acids, 73-78 N-(substituted) maleimides, 79-84

in mast cells, 63-64 oxidized LDL stimulation of PKC expression via in

P388D cells, 93-97 species differences, rat versus human COX, 67-71

Prostaglandin synthesis ovarian granulosa cells, 509-513 PGS-2 requirements in macrophages and fi

broblasts, 62-63 Prostate cancer

COX-2 up-regulation by PGE2, 163-169 12-LOX and multiple tumor suppressor genes in, 9,

41-50 LOX as prognostic marker, 46, 49 mechanism of suppressor gene inactivation,

46--48,50 status of, 41-45

Protein kinase A, tumor biology, 311-317 Protein kinase C

and activin A effects, 24~247 agonist-induced AA release, 124--125, 126 and cerami de effects on apoptosis, 14~147, 148 and EGF-induced 12-LOX, 33, 36 integrin activation, 55-59 macrophages, 479-483,485-489 melanoma cells, 306

cytokine receptor, 308 signaling pathways, 304

oxidized LDL stimulation in P388D 1 cells, 93-97 platelet signal transduction, 531-534 Raf-I homology, 422 THP-I cell differentiation, 491-495 vitamin E and, 123, 124--125, 126, 128

Protein kinases. see a/so Oncogenes/proto-oncogenes; Tyrosine kinases; specific kinases

cyclin dependent, 387-388 EGF regulation of 12-LOX expression, 9-14 MAP kinase, PLA2, and reactive oxygen species ac

tivation in keratinocytes, 289-293 membrane associated, see MAP kinases

Protein phosphatases PTK inhibitors and. 281, 284, 286 tumor biology, 311-317

Protein tyrosine kinases: see Tyrosine kinases Proto-oncogenes: see Oncogenes/proto-oncogenes Psoriasis, 33 Pti/alofi/icina, 330-334 Pulmonary artery rings, 213 Pulmonary system

alveolar macrophages, 281-287 mediators of vasodilation on rabbit lung, 561-566

Radicolol and activin A effects, 248 LPS-stimulated alveolar macrophages, 281-287

Radioreceptor assay, PAF, 459-464

597

Raf-I kinase, phosphatidic acid interaction, 422-425. 426 Rattlesnake venom, 106 Reactive oxygen species

activation in keratinocytes, 289-293 apoptosis, 405

Receptors cannabinoid: see Anandamide cell surface, integrin activation. 55-59 PAF

gene cloning and characterization, 347-354 gene structure and regulation. 197-203 localization in brain (rat), 357-362 radioreceptor assay, 459-464

PGE2, 168--169 prostanoid

cultured cell response to prostaglandins, 231-236 neuronal stimulant actions of prostacyclin and

mimetics, 211-217 site-directed mutagenesis, 205-209

signal transduction in platelets, 531-534 thromboxane receptor mimetics and antagonists, ef-

fects on vasculature and myometrium, 219-230 Receptor translocation, melanoma cells, 306 Regulation: see Gene expression Reproduction: see Gonadal tissue Reticulocytes, 15-LOX, 27-31 Retinoblastoma (RB) tumor suppressor gene in pros

tate cancer, 41-42 Retinoic acid

and activin A, 244--245 PAF receptor regulation, 20 I THP-I cell differentiation, 491-495

Retrosynthetic analysis, 498--50 I Reverse transcription-PCR

COX·2, 164--165 12-LOX, 3~37 PLA2, murine. 110-111 prostate cancer tumor suppressor genes. 44-45

Ro318220, 125. 126 Rouse sarcoma virus transformed cells. prostaglandin

expression. 62, 63

SC·57666, 70 SC-58125, 70. 159 Second messengers: see Signal transduction Secretory PLA2

differential activation in keratinocytes, 117-121 mast cell production of PGE2, 64, 65

Sensory nerves, prostacyclin mimetics and, 211-217 Serine threonine kinases, Raf-I, 422-425, 426 Signal transduction

apoptosis, 405 B cell production of IgE, 239 ceramide, 145-149 EGF

cells overexpressing erhB·HER, 393-397 keratinocyte cell line, 289-293 linolenic acid metabolites and, 319-322 12-LOX regulation, 9-14, 33

598

Signal transduction (cont.)

eicosapentaenoic acid effects on vascular cell growth, 399-403

guanylate cyclase, 271-277 integrin all~3 regulation, 58 lipid second messenger role in growth regulation

and cell cycle progression, 421-430 MAP kinase activation, 289-293 melanoma metastatic cascade, 303-309 PAF receptor, 199

macrophages, LPS and lipid moduiation of, 351-353 macrophage tumoricidal response, 371-377

pesticide effects in breast epithelial cells, 295-302 PGE2 regulation ofCOX-2, 169 PGS-2/ddd-2,61--65 platelets, 531-534 prostaglandin synthesis in ovarian granulosa cells,

509-513 protein phosphatases, 311-317 radicicol and, 281-287 rat liver macrophage activation

muramyl peptides and, 485-489 regulation of, 479-483

THP-I cell differentiation, 491-495 Single strand conformation polymorphism, prostate

cancer, 43, 44, 45 Site-directed mutagenesis

LTA4 hydrolase, 3-4 prostanoid receptors, 205-209

Skin 12-LOX distribution, 18-19 PLA2 synthase expression in keratinocytes, 117-121

Skin, keloids, 515-520 Smooth muscle cells, 211 Snake venom, 106 SPI, 12-LOX regulatory elements, 13 Spaceflight, 443-449 Species differences

cyclooxygenases.67-71 PLA2 expression. 115

Sphingomyelinases and ceramide, 145, 146 and germinal vesicle breakdown, 427, 429

Sphinogolipids, 421, 425, 427-429 SQ29,548, 225, 226. 228. 479 Src, 62. 186

alveolar macrophages. 281-282, 285-286, 287 melanoma metastatic cascade, 303

Staurosporine, 245 Subcellular localization

12-LOX A431 cells. 34-35 platelet-type in murine tissues. 15-19

15-LOX in mammalian cells, 27-31 Suicide inactivation

12-LOX, 191, 192-194 LTA4 hydrolase. 1-2,4-5

Sulprostone, 215, 216

Sulindac, 407 Sympathetic nervous system, 265-269 Synthons, retrosynthetic analysis, 498-50 I

Taprostone, 215 TATA-box,185 Tcells

apoptosis, 406 differentiation, eicosanoid formation during,

491-495 prostanoids (PGE2), 237-240

TEI-3356, 215, 216 TEI-9063, 215. 216 Teicoplanin, 525-529

Index

12-0-Tetradecanoylphorbol-13-acetate: see Phorbol esters, TPA

TGF: see Transforming.growth factor-a; Transform-ing growth factor-~

Th2 lymphocyte development, 238 Thapsigargin, 293 THIOAMID-PC. 118. 120, 121 Thioamine L T A4 hydrolase inhibitor, 6 Thiol reagents, 3, 64, 118 Thp-I cell differentiation, 491-495 Thromboxane

activin and, 244 vitamin E and, 123

Thromboxane A2, 525 apoptosis, 406 eicosapentaenoic acid mechanism of action. 399-400 7-oxabicyclo[2.2.1] heptane derivatives, 497-501

Thromboxane 8 2, activin A and, 246 Thromboxane derivatives. 7-oxabicyclo[2.2.1] hep

tane, 497-501 Thromboxane receptor mimetics and antagonists, um

bilical artery and myometrium effects, 219-230

Thyroid hormone, PAF receptor regulation, 20 I Tissue distribution

activins,243 12-LOX, platelet-type, 15-19 PAF receptor, 199-200,351 PLA2,115

TNF: see Tumor necrosis factor-a Tocopherol, myoblastic cell AA release, 123-128 Total body irradiation, murine AIDs cure with,

451-457 TP A: see Phorbol esters, TP A Transcellular prostaglandin synthesis model, 64--65 Transcription factors, PGE synthase-2. 139-144 Transforming growth factor-a

keratinocyte proliferation, 289 ovarian granulosa cell response, 509-513

Transforming growth factor-~ activin A and, 243, 244 granulosa cells, 512-513 integrin a"~3 regulation, 56 PAF receptor regulation. 200-201

Index

Tumor biology apoptosis, 405, 418 breast tissue

DDT and arochlor effects in epithelial cells, 295-302

IFN-yand IL-6 regulation of eicosanoid-like com-pounds in cancer cells, 179-183

carcinogenesis in COX-deficient mouse, 90 integrin activation, 55--59 macrophage cytotoxicity

MTP-Pe-induced, 485-489 PAF-mediated tumoricidal response, 371-377

melanoma metastatic cascade, 303-309 naturin-2, 541-548 NSAIDS and Gardner's syndrome cell growth,

433-440 peroxynitrite effects on apoptosis in HL-60 cells,

413--418 prostate cancer, 41-50 protein phosphatases, 311-317

Tumor necrosis factor-a activin A and, 246, 248 apoptosis, 405, 407 bone changes, 383, 384 and ceramide, 145, 146, 147, 148 eicosanoids and, 182 integrin allJ33 regulation, 56 macrophage

LPS and MTP-PE mediated, 485-489 PAF-induced, 371, 372, 373, 374. 377

necrotizing enterocolitis. 379-382 Tumor necrosis factor-a (cant.)

PTK inhibitors and, 281, 283, 284, 287 renal cytochrome P450-dependent eicosanoids.

257-260 Tumor promoters

phorbol esters: see Phorbol esters PLA2 differential activation in keratinocytes.

117-121 TXA2: see Thromboxane A2 Tyrosine kinases

DDT and arochlor effects in breast epithelial cells, 295--302

EGF regulation of 12-LOX expression, 9-14 signal transduction, 320, 321

linolenic acid metabolism of cells overexpressing Erbb-2IHER2 oncogene, 393-397

liver macrophages release of AA, PLA2 and, 479--483

melanoma metastatic cascade, 303-309 radicicol, 281-287

Tyrosyl reagents, L T A4 hydrolase inactivation, 2-3

599

Tyrphostin, 247, 248

U937 cells, 372, 413, 491 U46619. 225. 226. 227. 229. 261,561-566 Umbilical artery, thromboxane receptor mediated ac

tion. 219, 22{}-22 I. 225--226

Variable number of tandem repeats (VNTR), 43-44 Vascular cells

COX-2.139-144 growth, eicosapentaenoic acid effects, 399--403 integrin aIlJ33 regulation, 56 teicoplanin effects, 525--529

Vascular tissue atherosclerosis

eicosapentaenoic acid mechanism of action in, 399--403

lipoprotein effects in PKC-COX in macrophages, 93-97

15-LOX,27 cytochrome P450-dependent eicosanoids, 255--260 12-HPETE in pathogenesis of cerebral vasospasm,

21-25 joint perfusion, 265--269 pulmonary vasodilation in rabbit, 561-566 thromboxane receptor mediated action in umbilical

artery preparations, 219, 22{}-22I. 225-226 Vas deferens, prostacyclin mimetics, 211, 214-216 Vimentin, 304-305, 317 Vitamin A derivatives: see Retinoic acid Vitamin D and metabolites

bone changes, 83 and ceramide, 145. 146 THP-I cell differentiation, 491--495

Vitamin E. myoblastic cell AA release. 123-128 VNTR, in prostate cancer, 43 v-src, 62, 186

W256 cell apoptosis, 407, 408. 409 White blood cells, 182: see also Lymphocytes; HL-60

cells 12-LOX, 191-195 15-LOX, 27-31 THP-I cell differentiation, 491--495

Wortmannin, 533-534

Xenopus laevis, 555--559 Xenopus oocytes, 421, 425, 427--429

Zymosan AA release in rat liver macrophages, 479, 480, 481,

482 microglia, 362

Documents

CONTRIBUTORS - Home - Springer978-1-4899-1813...A.B. Hancock, Jr. Memorial Laboratory for Cancer Research Department of Biochemistry Center in Molecular Toxicology Vanderbilt Univ